Disease · MONDO_0006206

fallopian tube carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. fallopian tube carcinoma. Diseases, record MONDO_0006206. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006206

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: fallopian tube carcinoma; Open Targets
Open Targets ID: MONDO_0006206; Open Targets
Other names: cancer of fallopian tube, cancer of the fallopian tube, carcinoma of fallopian tube, carcinoma of the fallopian tube, fallopian tube Ca, fallopian tube cancer; Open Targets
Disease Ontology: DOID:1963; Disease Ontology
NCI Thesaurus: C3867; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 50 drugs, from FDA; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIRAPARIB TOSYLATE MONOHYDRATE	CHEMBL3989922	Small molecule	Approval	FDA	1	0	0	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	26	26	26	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	21	21	21	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
OREGOVOMAB	CHEMBL2107917	Antibody	Phase 3	ClinicalTrials.gov	3	3	1	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets73

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
PARP1	PARP 1, 2 and 3	5	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor	Approval	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	PARP 1, 2 and 3	5	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor	Approval	https://conductscience.org/library/genes/10038	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 73

See all 73 targets

Trials61

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03740165	Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)	Phase 3	1,367	2025-09-12	Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms	OLAPARIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01239732	A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer	Phase 3	1,021	2016-06-10	Ovarian Cancer	BEVACIZUMAB, CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00191646	An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy	Phase 3	919	2010-09-09	Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms	CARBOPLATIN, GEMCITABINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT05116189	Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).	Phase 3	643	2026-03-09	Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms	BEVACIZUMAB, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00434642	A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma	Phase 3	484	2011-11-03	Ovarian Cancer	BEVACIZUMAB, CARBOPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT05092360	Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)	Phase 3	456	2025-08-28	Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01610206	A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer	Phase 2	148	2021-02-25	Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer	GEMCITABINE, PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT00296816	TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary	Phase 2	132	2012-08-23	Ovarian Cancer	BEVACIZUMAB, DOCETAXEL, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT05483933	Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers	Phase 1	86	2025-12-23	Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma	DOXORUBICIN, MIRVETUXIMAB SORAVTANSINE	Its record names the disease	ClinicalTrials.gov
NCT00721162	Study of Ramucirumab in Ovarian Cancer	Phase 2	60	2014-06-18	Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma	RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 61

See all 61 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: deaths from any cause	225 of 322	244 of 321	643	NCT05116189	Trial comparisons
Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: serious adverse events	178 of 320	122 of 318	638	NCT05116189	Trial comparisons
Carboplatin and Gemcitabine + Bevacizumab vs Carboplatin and Gemcitabine + Placebo: serious adverse events	90 of 247	59 of 233	480	NCT00434642	Trial comparisons
Gemcitabine vs Gemcitabine + Pazopanib: Number of Participants With Adverse Events	73 of 73	75 of 75	148	NCT01610206	Trial comparisons
Gemcitabine vs Gemcitabine + Pazopanib: deaths from any cause	54 of 73	63 of 75	148	NCT01610206	Trial comparisons
Gemcitabine vs Gemcitabine + Pazopanib: serious adverse events	20 of 73	63 of 75	148	NCT01610206	Trial comparisons
Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetixumab + SL-172154: Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab	20 of 21	65 of 65	86	NCT05483933	Trial comparisons
Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetuximab + SL-172154: deaths from any cause	12 of 21	30 of 65	86	NCT05483933	Trial comparisons
Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetuximab + SL-172154: serious adverse events	4 of 21	17 of 65	86	NCT05483933	Trial comparisons
Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetuximab + SL-172154: Immunogenicity to SL-172154	0 of 20	38 of 60	80	NCT05483933	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials48

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37227734	RESULT	1	PubMed
35690772	RESULT	1	PubMed
34686353	RESULT	1	PubMed
33538338	RESULT	1	PubMed
33388455	RESULT	1	PubMed
33102004	RESULT	1	PubMed
32690392	RESULT	1	PubMed
32305099	RESULT	1	PubMed
32224896	RESULT	1	PubMed
29356953	RESULT	1	PubMed

1 to 10 of 48

See all 48 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006206

GET https://conductscience.org/api/diseases/v1/MONDO_0006206/drugs?page=2

API reference For AI assistants